Author

Susan Henry

Observed names: S. Henry, S.H. Henry, Susan H. Henry, Susan Hayes Henry

Institutions: Scholar Rock (United States), Syros Pharmaceuticals (United States)

Observed institutions: Scholar Rock (United States), Acucela (United States), Syros Pharmaceuticals (United States)

ORCID: 0000-0002-6922-2686

Observed ORCID: 0000-0002-6922-2686

OpenAlex ID: A5000117710

Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity

2015 · Claes Bavik, Susan Hayes Henry, et al. · PLoS ONE · 81

Pharmacotherapy for metabolic and cellular stress in degenerative retinal diseases

2019 · Ryo Kubota, Jeff Gregory, et al. · Drug Discovery Today · 20

Emixustat Reduces Metabolic Demand of Dark Activity in the Retina

2019 · Ryo Kubota, David J. Calkins, et al. · Investigative Ophthalmology & Visual Science · 19

518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors

2021 · M. Sharma, B. Bashir, et al. · Annals of Oncology · 11

Comparison of Inhibitor and Substrate Selectivity between Rodent and Human Vascular Adhesion Protein-1

2020 · Ryo Kubota, Michael J. Reid, et al. · Mediators of Inflammation · 7

SY5609, a Potent and Selective CDK7 Inhibitor, Potentiates BTK Inhibitor Activity in Mantle Cell Lymphoma Preclinical Models

2021 · Liv Johannessen, Susan Henry, et al. · Blood · 5

Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.

2023 · Babar Bashir, Manish Sharma, et al. · Journal of Clinical Oncology · 4

Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).

2023 · Dejan Juric, Debra L. Richardson, et al. · Journal of Clinical Oncology · 4

13P SY-5609, a highly potent and selective oral CDK7 inhibitor, exhibits robust antitumor activity in preclinical models of KRAS mutant cancers as a single agent and in combination with chemotherapy

2021 · S.H. Henry, L. Johannessen, et al. · Annals of Oncology · 2

14P Preclinical evaluation of intermittent dosing regimens on antitumor and PD activity of SY-5609, a potent and selective oral CDK7 inhibitor, in ovarian cancer xenografts

2021 · L. Johannessen, W. Dworakowski, et al. · Annals of Oncology · 1

666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients

2023 · Timothy Yap, Ulka N Vaishampayan, et al. · Journal for ImmunoTherapy of Cancer

Visual Cycle Modulators (VCMs) as Inhibitors of Retinal Neovascularization

2012 · Susan Henry, Ewa Budzynski, et al. · Investigative Ophthalmology & Visual Science

Works count: 12

Citation count: 154

H-index: 5

I10-index: 4